Incyte
INCY
$104.40
+0.71%
Incyte is a biotechnology company focused on the discovery and development of small-molecule drugs, primarily in oncology and dermatology. The company is a recognized leader in hematology with its flagship drug Jakafi, and it has built a diversified portfolio including marketed products in oncology and its first dermatology product, Opzelura. The current investor narrative is heavily focused on strategic growth beyond Jakafi, particularly highlighted by a recent $1.25 billion bet to acquire a late-stage drug candidate for a rare bleeding disorder, signaling a major expansion of its hematology franchise and a push to secure its next blockbuster.…
INCY
Incyte
$104.40
Related headlines
Investment Opinion: Should I buy INCY Today?
Rating & Thesis: Hold. Incyte is a fundamentally strong company in a strategic transition, but the near-term risk/reward is balanced as the market awaits proof points from its major acquisition. The analyst consensus leans bullish-to-neutral, but recent downgrades and a wide estimate range suggest caution is warranted.
Supporting Evidence: The company trades at a forward P/E of 10.72x, which is a discount to its trailing P/E of 14.98x and appears reasonable for its 27.84% YoY revenue growth and 19.86% net margin. It generates powerful free cash flow ($1.35B TTM) and has a pristine balance sheet (D/E of 0.013). However, the stock's short-term underperformance (-6.94% vs. SPY over 3 months) and consolidation below its 52-week high indicate a lack of immediate catalysts to drive the price higher toward analyst implied targets.
Risks & Conditions: The two biggest risks are the integration/outcome of the $1.25B acquisition and a deceleration in core revenue growth below 20%. This Hold rating would upgrade to a Buy if the stock breaks above key resistance at $112.29 on positive clinical data for the acquired asset, or if the forward P/E compresses further toward 9x without a deterioration in growth prospects. It would downgrade to a Sell if quarterly revenue growth decelerates below 15% or if the acquisition shows clear signs of failure. The stock is currently fairly valued relative to its near-term growth profile and risk.
Sign up to view all
INCY 12-Month Price Forecast
Incyte presents a compelling but transitional story. The fundamentals are robust: high growth, profitability, and financial strength. However, the stock is in a holding pattern, digesting its 43.87% annual gain and awaiting catalysts from its major strategic bet. The neutral stance reflects the balance between solid underlying performance and the elevated uncertainty introduced by the large acquisition. The stance would upgrade to bullish on a confirmed breakout above $112 with volume, signaling the market's endorsement of the growth strategy. It would turn bearish if the stock breaks below $90 on worsening fundamentals, indicating the acquisition is being perceived as a value-destructive misstep.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Incyte's 12-month outlook, with a consensus price target around $135.72 and implied upside of +30.0% versus the current price.
Average Target
$135.72
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$84 - $136
Analyst target range
Analyst coverage for Incyte appears limited in the provided data, with only 8 analysts providing estimates for revenue and EPS. The institutional ratings data shows recent actions from firms like Jefferies (downgraded to Hold from Buy in March 2026), UBS (Neutral), Barclays (Overweight), and HC Wainwright (reiterated Buy). This pattern indicates a generally positive but cautious sentiment, with no outright Sell ratings in the recent sample. The consensus leans bullish-to-neutral. The analyst estimates provide a target range for future performance. The average revenue estimate for the next period is $4.64 billion, with a low of $4.42 billion and a high of $5.15 billion. The average EPS estimate is $3.90, ranging from $3.66 to $4.46. The wide spread between the low and high revenue estimates (approximately $730 million) signals meaningful uncertainty among analysts regarding the company's near-term growth trajectory, likely influenced by the integration and prospects of new acquisitions like the recent $1.25 billion deal. A tight consensus would indicate stronger conviction, which is not currently the case.
Bulls vs Bears: INCY Investment Factors
The bull case, anchored in strong fundamentals (27.8% revenue growth, 19.9% net margin, robust FCF) and a strategic growth investment, currently holds stronger evidence than the bear case. The bear points largely revolve around execution risks and sentiment, whereas the bull points are grounded in concrete financial performance. The single most important tension in the investment debate is the success of the $1.25B acquisition in delivering a new blockbuster to reduce reliance on Jakafi. If the acquisition integrates smoothly and the candidate meets its potential, the stock could re-rate higher. If it stumbles, the company's growth narrative and premium valuation support could weaken significantly.
Bullish
- Strong Revenue Growth & Diversification: Q4 2025 revenue grew 27.84% YoY to $1.51B, driven by flagship Jakafi ($958.5M) and the emerging Opzelura ($207.3M). This accelerating trajectory from Q1's $1.05B demonstrates successful portfolio expansion beyond a single product.
- Robust Profitability & Cash Generation: Net margin expanded to 19.86% in Q4 2025, with a gross margin of 90.88%. The company generates powerful free cash flow ($1.35B TTM) and has a strong balance sheet with a negligible debt-to-equity ratio of 0.013, providing ample fuel for R&D and acquisitions.
- Attractive Valuation with Growth Discount: The forward P/E of 10.72x, based on estimated EPS of $3.90, represents a significant discount to the trailing P/E of 14.98x, implying the market is pricing in substantial earnings growth. This valuation is reasonable for a profitable biotech with 27.8% revenue growth.
- Strategic Growth Investment: The recent $1.25B acquisition of a late-stage drug candidate for a rare bleeding disorder is a major strategic bet to secure the next blockbuster and expand its hematology franchise, directly addressing the 'beyond Jakafi' narrative.
Bearish
- Heavy Reliance on Jakafi Franchise: Despite diversification, Jakafi still contributed 63.6% of Q4 2025 revenue ($958.5M of $1.51B). The company's near-term fortunes remain highly tied to this single product's performance and patent lifecycle.
- Analyst Uncertainty & Sentiment Shift: Only 8 analysts provide estimates, with a wide revenue forecast range ($4.42B to $5.15B), signaling low conviction. Recent actions like Jefferies' downgrade to Hold in March 2026 reflect growing caution despite the overall bullish-to-neutral consensus.
- Short-Term Consolidation & Underperformance: The stock has underperformed the S&P 500 by -6.94% over the past 3 months and is trading near the lower end of its recent $90-$108 consolidation range at $98.22. This suggests momentum has stalled as the market digests the large acquisition.
- Integration & Execution Risk on Major Deal: The $1.25B acquisition introduces significant integration and clinical/regulatory execution risk. Failure of the acquired candidate or cost overruns could pressure the strong balance sheet and dilute the attractive ROE of 24.90%.
INCY Technical Analysis
The stock is in a sustained uptrend over the past year, with a 1-year price change of +43.87%, significantly outperforming the S&P 500's +24.99% gain. As of the latest close of $98.22, the price is trading at approximately 73% of its 52-week range ($66.74 to $112.29), indicating it is in the upper-mid portion of the range and retains substantial momentum from the yearly advance. Recent short-term momentum shows signs of consolidation and volatility; the stock gained +2.74% over the past month but underperformed the S&P 500's +15.14% gain over the past three months, posting a +8.20% return. This divergence suggests the stock is experiencing a pause or pullback within its longer-term uptrend, potentially digesting its significant yearly gains. Key technical support is anchored at the 52-week low of $66.74, while immediate overhead resistance sits near the 52-week high of $112.29. A decisive breakout above $112.29 would signal a resumption of the primary bullish trend, whereas a breakdown below the recent trading range could test lower support levels. The stock's beta of 0.79 indicates it is approximately 21% less volatile than the broader market, which is notable for a biotech stock and suggests it has exhibited lower systematic risk during the recent period of strong outperformance. The price action from the provided data shows the stock rallied sharply to a peak of $110.57 in early January 2026 but has since traded in a choppy, consolidative pattern between approximately $90 and $108. The most recent data point of $98.22 on June 18, 2026, is near the lower end of this recent consolidation range. The relative strength metrics confirm the short-term underperformance, with a 3-month relative strength of -6.94 against the S&P 500.
Beta
0.79
0.79x market volatility
Max Drawdown
-18.3%
Largest decline past year
52-Week Range
$67-$112
Price range past year
Annual Return
+55.2%
Cumulative gain past year
| Period | INCY Return | S&P 500 |
|---|---|---|
| 1m | +7.5% | -1.6% |
| 3m | +13.2% | +11.7% |
| 6m | +3.9% | +6.3% |
| 1y | +55.2% | +22.2% |
| ytd | +2.9% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INCY Fundamental Analysis
Revenue growth has been robust and accelerating. For Q4 2025, revenue was $1.51 billion, representing a strong year-over-year growth rate of 27.84%. This follows sequential quarterly revenues of $1.37 billion in Q3, $1.22 billion in Q2, and $1.05 billion in Q1 2025, indicating a clear upward trajectory throughout the fiscal year. The growth is driven by the core Jakafi franchise, which contributed $958.5 million in the latest period, and the emerging dermatology product Opzelura, which contributed $207.3 million, showcasing successful diversification. The company is solidly profitable with expanding margins. Net income for Q4 2025 was $299.3 million, translating to a net margin of 19.86%. The gross margin remains exceptionally high at 90.88%, consistent with its biopharmaceutical business model. Profitability has improved markedly from the volatility seen in 2024, where Q2 2024 showed a net loss of -$444.6 million due to high R&D charges; the progression to consistent quarterly profits in 2025 demonstrates effective cost management and the maturation of its commercial portfolio. Balance sheet health is strong, characterized by high liquidity and minimal debt. The current ratio is a robust 3.32, indicating ample short-term assets to cover liabilities. The debt-to-equity ratio is negligible at 0.013, reflecting a virtually debt-free balance sheet. Free cash flow generation is powerful, with TTM free cash flow of $1.35 billion, providing significant internal funding for R&D and business development, as evidenced by the recent large acquisition announcement. Return on Equity (ROE) of 24.90% is strong and indicates efficient use of shareholder capital.
Quarterly Revenue
$1.5B
2025-12
Revenue YoY Growth
+0.27%
YoY Comparison
Gross Margin
+0.90%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INCY Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing twelve-month PE ratio is 14.98x, while the forward PE is lower at 10.72x based on estimated EPS of $3.90. The discount of the forward PE suggests the market anticipates significant earnings growth, which aligns with the company's revenue trajectory and recent strategic investments. Compared to typical biotechnology industry averages, Incyte's valuation presents a mixed picture. Its trailing PE of 14.98x is generally in line with or below that of many profitable mid-to-large cap biotechs, which often trade at higher multiples due to growth expectations. Its Price-to-Sales (PS) ratio of 3.75x and EV/Sales of 2.98x are reasonable for a company with its growth profile and high margins, likely not representing a significant sector premium. Historically, Incyte's own valuation has fluctuated. The current trailing PE of 14.98x sits below its recent historical highs seen in Q3 2025 (PE of 9.78x on higher earnings) and is significantly below the elevated multiples seen during periods of high speculative growth or lower earnings in 2021-2022 (PEs often above 30x). This suggests the current valuation is not stretched relative to its own history and may reflect a more mature, cash-generative phase of the business, potentially offering a reasonable entry point if growth expectations are met.
PE
15.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -7x~186x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Incyte's primary financial risk is revenue concentration, with the Jakafi franchise still constituting nearly two-thirds of quarterly sales. While profitability is strong now, the company has shown volatility, as evidenced by the Q2 2024 net loss of -$444.6M due to high R&D charges. The recent $1.25B acquisition, while funded from a strong balance sheet, introduces execution risk; any clinical setbacks or integration issues could pressure the company's impressive 24.90% ROE and consume its substantial free cash flow, potentially slowing other pipeline investments.
Market & Competitive Risks: The stock's valuation, while reasonable, is not deeply discounted. A forward P/E of 10.72x relies on sustained high growth. Should revenue growth decelerate towards the analyst low estimate of $4.42B (implying slower growth), valuation compression is a clear risk. Competitive and regulatory pressures in oncology and dermatology are perpetual threats. The stock's low beta of 0.79 offers some insulation from macro volatility, but sector-specific headwinds like drug pricing pressures or clinical trial failures for peers could negatively impact sentiment across the biotech group.
Worst-Case Scenario: The worst-case scenario involves a double-whammy: the new $1.25B acquisition fails in late-stage trials, resulting in a significant write-down, concurrent with a slowdown in Jakafi growth or unexpected competition. This could trigger analyst downgrades, a loss of investor confidence in management's capital allocation, and a rapid derating of the stock. The realistic downside could see the stock retreat to its 52-week low of $66.74, representing a potential loss of approximately -32% from the current price of $98.22. The recent maximum drawdown of -18.33% shows the stock is capable of sharp corrections within its uptrend.
FAQ
The key risks are: 1) Product Concentration: Jakafi still drives ~64% of revenue, creating vulnerability. 2) Acquisition & Execution Risk: The $1.25B bet on a new drug candidate could fail clinically or be poorly integrated, destroying value. 3) Growth Deceleration: Revenue growth slowing from 27.8% could trigger multiple compression from the current forward P/E of 10.72x. 4) Sentiment & Technical Risk: The stock is consolidating after a strong run and recent analyst downgrades (e.g., Jefferies to Hold) show sentiment is fragile; a break below $90 could trigger further selling.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $98 and $112, as steady execution supports the current valuation. The Bull Case (30% probability) targets $112 to $125, driven by success in the new acquisition and multiple expansion. The Bear Case (15% probability) warns of a drop to between $67 and $90 if the acquisition fails and growth stalls. The most likely scenario is the Base Case, which assumes the company meets analyst revenue estimates of ~$4.64B without major surprises.
INCY appears fairly valued relative to its near-term prospects. Its forward P/E of 10.72x is a discount to its trailing P/E of 14.98x, implying the market is pricing in significant earnings growth which aligns with its 27.8% revenue growth trajectory. Compared to many high-growth but unprofitable biotechs, Incyte's valuation is grounded in actual profits and cash flow. The valuation implies the market expects successful execution of the growth plan beyond Jakafi but is not paying a premium for it yet, awaiting proof from the recent acquisition. It is not obviously overvalued or undervalued.
INCY is a good buy for investors seeking exposure to a profitable, growing biotech with a clear diversification strategy, but it may not be optimal for those seeking immediate catalysts. The stock offers a reasonable valuation (10.72x forward P/E) for its 27.8% growth and has 32% downside to its 52-week low versus 14% upside to its 52-week high, indicating a balanced but slightly skewed risk/reward. It is a good buy for patient, growth-oriented investors who believe in management's ability to successfully integrate its $1.25B acquisition. Traders looking for short-term momentum should wait for a breakout above $112.29.
INCY is more suitable for a medium-to-long-term investment horizon (12-24 months minimum). The company's strategic shift and the clinical/regulatory timeline for its new acquisition require time to play out. Its low beta of 0.79 suggests lower volatility than typical biotechs, making it less ideal for short-term trading which thrives on volatility. The lack of a dividend also negates an income focus. Given the need to validate the 'beyond Jakafi' narrative, investors should be prepared to hold through potential near-term volatility to realize the long-term growth story.